BioHealth News
Annapolis’ Alphyn Granted U.S. Patent Covering First-in-Class Treatment for Atopic Dermatitis
ANNAPOLIS, Md., Dec. 10, 2024 /PRNewswire/ -- Alphyn, a clinical-stage dermatology company developing first-in-class Multi-Target Therapeutics®, announced today that the U.S. Patent and Trademark Office (USPTO) has…
Read MoreFrederick’s Alithea Genomics Launches Full-Length DRUG-Seq to Unlock Full Power of Transcriptomics for Drug Discovery
Multiplexed, extraction-free, full-length library preparation technology facilitates large-scale RNA sequencing, combining ever more content with high throughput FREDERICK, Md., Dec. 9, 2024 /PRNewswire-PRWeb/ -- Alithea Genomics,…
Read MoreFY25 MBIA Commercialization Innovation Grant Applications Open December 10
The Maryland Business Innovation Association (MBIA), with support from TEDCO, has announced the launch of the FY25 MBIA Commercialization Innovation Grant (MCIG). Designed to…
Read MoreBDC and Maryland Department of Commerce Announce Board of Estimates Approval of Conditional Loan for 4MLK Flex Lab Space
Baltimore, MD—The Baltimore Development Corporation (BDC) and the Maryland Department of Commerce are pleased to announce the Baltimore City Board of Estimates' approval of…
Read MoreChildren’s National, FDA collaborate to advance pediatric device regulatory tools
WASHINGTON (Dec. 4, 2024) — In a significant collaboration to help advance pediatric health, Children’s National Hospital and the U.S. Food and Drug Administration’s…
Read MoreAdvancing MRI Metabolic Imaging: Join NCI’s Upcoming Technology Opportunity Webinar
The National Cancer Institute (NCI) Technology Transfer Center is hosting a webinar on an exciting new technology that could revolutionize MRI metabolic imaging. Scheduled…
Read MoreCartesian Reports Positive Phase 2b Results for Descartes-08 in Myasthenia Gravis and Previews Phase 3 Trial
FREDERICK, Md., Dec. 03, 2024 (GLOBE NEWSWIRE) -- Cartesian Therapeutics, Inc. (NASDAQ: RNAC) (the “Company”), a clinical-stage biotechnology company pioneering mRNA cell therapy for…
Read MoreGaithersburg’s Shuttle Pharma Begins Phase 2 Trial of Ropidoxuridine for Glioblastoma at UVA Cancer Center
GAITHERSBURG, Md., Nov. 26, 2024 (GLOBE NEWSWIRE) -- Shuttle Pharmaceuticals Holdings, Inc. (Nasdaq: SHPH) (“Shuttle Pharma”), a discovery and development stage specialty pharmaceutical company…
Read MoreRevolutionizing Respiratory Care: Linshom Medical’s Journey to Innovation and Recognition on BioTalk
[vc_row type="in_container" full_screen_row_position="middle" column_margin="default" column_direction="default" column_direction_tablet="default" column_direction_phone="default" scene_position="center" text_color="dark" text_align="left" row_border_radius="none" row_border_radius_applies="bg" overlay_strength="0.3" gradient_direction="left_to_right" shape_divider_position="bottom" bg_image_animation="none"][vc_column column_padding="no-extra-padding" column_padding_tablet="inherit" column_padding_phone="inherit" column_padding_position="all" column_element_spacing="default" background_color_opacity="1" background_hover_color_opacity="1" column_shadow="none"…
Read MoreUniversity of Maryland Institute for Health Computing Celebrates Second Anniversary
Uncovering bias in AI models used in medical diagnosis. Identifying patients with potentially life-threatening antibiotic-resistant infections. Predicting the spread of disease with advanced computing.…
Read MoreArlington Capital Partners Acquires TEAM Technologies
Washington, D.C. – November 25, 2024 – Arlington Capital Partners (“Arlington”), a Washington, D.C.-area private investment firm specializing in government regulated industries, today announced it…
Read MoreMTD: Michelle Tarver faces challenges as the FDA’s new CDRH leader. But patient groups, industry are optimistic.
Michelle Tarver, the new leader of the Food and Drug Administration’s medical device center, faces significant challenges ahead. Tarver is taking over as director…
Read MoreTransforming Emergency Medicine: Dr. Eric Edwards and MedPhlow’s Life-Saving Innovations on BioTalk
[vc_row type="in_container" full_screen_row_position="middle" column_margin="default" column_direction="default" column_direction_tablet="default" column_direction_phone="default" scene_position="center" text_color="dark" text_align="left" row_border_radius="none" row_border_radius_applies="bg" overlay_strength="0.3" gradient_direction="left_to_right" shape_divider_position="bottom" bg_image_animation="none"][vc_column column_padding="no-extra-padding" column_padding_tablet="inherit" column_padding_phone="inherit" column_padding_position="all" column_element_spacing="default" background_color_opacity="1" background_hover_color_opacity="1" column_shadow="none"…
Read MoreBARDA Launches SPARK Hub Prize Challenge to Advance Pediatric Medical Countermeasures
The Biomedical Advanced Research and Development Authority (BARDA) has announced the launch of the SPARK Hub Prize Challenge, offering up to $50,000 in funding…
Read MoreTearSolutions, Inc. Secures $3M Series B Funding
CHARLOTTESVILLE, Va., Nov. 21, 2024 (GLOBE NEWSWIRE) -- TearSolutions, Inc., a privately held biotech company developing potentially disruptive therapies for the treatment of ocular surface…
Read More